Cyanine Nanocage Activated by Near-IR Light for the Targeted Delivery of Cyclosporine A to Traumatic Brain Injury Sites

• DOI: 10.1021/acs.molpharmaceut.0c00589
• Publication Date: 2020-08-19T18:49:25Z
• Authors: Caroline E. Black; Eugene Zhou; Caitlin DeAngelo; Isaac Asante; Rong Yang; Nicos A. Petasis; Stan G. Louie; Mark Humayun
• Keywords: Cyanine

More than 2.8 million annually in the United States are afflicted with some form of traumatic brain injury (TBI), where 75% victims have a mild TBI (MTBI). risk is higher for individuals engaging physical activities or involved accidents. Although MTBI may not be initially life-threatening, large number these can develop cognitive and dysfunctions. These late clinical sequelae been attributed to development secondary injuries that occur minutes days after initial impact. To minimize damage from TBI, it critical diagnose treat patients within first "golden" hour TBI. would very helpful quickly determine locations direct treatment selectively affected sites, this remains challenge. Herein, we disclose our novel strategy target cyclosporine A (CsA) into without need locate exact location lesion. Our approach based on cyanine dye nanocage attached CsA, known therapeutic agent associated unacceptable toxicities. In its caged form, CsA inactive, while near-IR light photoactivation, resulting fragmentation leads selective release at sites.